Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells

Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells

Background The survival benefit observed in children with neuroblastoma (NB) and minimal residual disease who received treatment with anti-GD2 monoclonal antibodies prompted our investigation into the safety and potential clinical benefits of anti-CD3×anti-GD2 bispecific antibody (GD2Bi) armed T cel...

Full description

Bibliographic Details
Main Authors: Qin Liu, Archana Thakur, Lawrence G Lum, Dana Schalk, Anthony F Shields, Daniel W Lee, Nai-Kong V Cheung, Maxim Yankelevich, Shakeel Modak, Roland Chu, Jeffrey Taub, Alissa Martin, Amy Schienshang, Sarah Whitaker, Katie Rea
Format: Article
Language:English
Published: BMJ Publishing Group 2024-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/3/e008744.full

Internet

https://jitc.bmj.com/content/12/3/e008744.full

Similar Items